Pendal Group Ltd bought a new stake in Natera Inc (NASDAQ:NTRA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 37,288 shares of the medical research company’s stock, valued at approximately $893,000. Pendal Group Ltd owned approximately 0.06% of Natera as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Zions Bancorporation acquired a new stake in shares of Natera in the third quarter valued at about $6,319,000. Meeder Asset Management Inc. increased its stake in shares of Natera by 920.5% in the third quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after buying an additional 7,576 shares during the period. Wells Fargo & Company MN increased its stake in shares of Natera by 6.9% in the third quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock valued at $1,266,000 after buying an additional 3,411 shares during the period. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Natera in the third quarter valued at about $1,035,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Natera in the third quarter valued at about $1,915,000. Hedge funds and other institutional investors own 87.90% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. BidaskClub cut Natera from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 13th. Cowen reissued a “buy” rating and issued a $30.00 price target on shares of Natera in a research note on Friday, November 9th. TheStreet cut Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. Finally, JPMorgan Chase & Co. assumed coverage on Natera in a research note on Friday, October 5th. They set a “neutral” rating and a $26.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Natera currently has an average rating of “Buy” and an average price target of $28.25.
Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03). The company had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The firm’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) EPS. On average, equities research analysts anticipate that Natera Inc will post -2.11 earnings per share for the current fiscal year.
In other news, COO Steven Leonard Chapman sold 45,000 shares of the business’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the sale, the chief operating officer now owns 16,628 shares of the company’s stock, valued at approximately $418,360.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $24.27, for a total value of $4,045,008.09. Following the completion of the sale, the insider now directly owns 481,975 shares of the company’s stock, valued at approximately $11,697,533.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,014,988 shares of company stock valued at $48,674,710. Corporate insiders own 13.18% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: What is a put option?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.